摘要
目的：观察吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法：38例初治NSCLC给予吉西他滨1000mg／m^2，d1、d8，静脉滴注30分钟，长春瑞滨25mg／m^2，d1、d8，静脉推注，21d为1个周期，至少治疗2个周期。结果：全组38例均可评价，无CR，PR13例，总有效率（CR＋PR）34．2％（13／38），SD31．6％（12／38），PD21．1％（8／38），中位生存期为11个月，疾病进展时间为5．9个月；1年生存率及2年生存率分别为44．7％（17／38）和23．7％（9／38）。血液学毒性反应主要是Ⅰ～Ⅱ度白细胞下降占73．7％（28／38），Ⅲ～Ⅳ度白细胞下降占10．5％（4／38），Ⅰ-Ⅱ度血红蛋白及血小板下降分别占26．3％（10／38）和31．6％（12／38），非血液毒性包括食欲减退、Ⅰ～Ⅱ度恶心及呕吐、局部静脉炎等，所有不良反应经对症处理及支持治疗后均恢复正常。结论：吉西他滨联合长春瑞滨组成GN方案对于晚期NSCLC疗效较好，毒副反应可耐受，值得临床推广。
Objective：To observe the clinical efficacy and side effect of gemcitabine and vinorelbine combinations in advanced non-small-cell lung cancer. Methods： Thirty-eight patients were treated with gemcitabine （1 000mg/m^2,d1, d8 ） plus vinorelbine （25mg/m^2, d1, d8 ）, the treatment schedule was recycled every 21 days, at least for 2 cycles. Results： The totle response rate （ CR ＋ PR） of thirty-eight patients was 34. 2% （12/38）. Median survival time and TrP was 11 month and 5.9 month, respectively. The l-year and 2-year survival rate was 44. 7% and 23.7%, respectively. The main adverse effect was myelosuppression. There wasn＇t grade Ⅲ/Ⅳ nausea and vomiting. All adverse effects were tolerated by sustaining therapy and allopathy. Condutions： Gemcitabine combined vinorelbine regimen （GN） is an active and well-tolerated and represents an option for the treatment of patients with advanced NSCLC.
出处
《临床肿瘤学杂志》
CAS
2006年第8期607-608,614,共3页
Chinese Clinical Oncology
